Latest OncoZenge News & Updates

See the latest news and media coverage for OncoZenge. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
OncoZenge

Clinical-stage pharmaceutical company developing oral pain treatments

oncozenge.se
Headquarters
Stockholm, Sweden
Company type
Public company
Number of employees
4–10
Industry
Pharmaceuticals

Last updated

Latest news about OncoZenge

In short: OncoZenge launched its Phase III BEAM-Pain trial for BupiZenge after receiving European regulatory approval and securing vital funding.

Company announcements

OncoZenge

OncoZenge expands global patent coverage for BupiZenge

The company submitted applications in 17 jurisdictions ahead of deadlines to secure intellectual property rights through 2045, aiming to attract regional licensees before trial results.

Unlock all announcements with a

Media coverage

BioStock

OncoZenge on the rights issue and the way forward

OncoZenge is now conducting a rights issue of SEK 33.3 million, covered to approximately 80 percent and backed by a group of well-known investors, including Life Science Invest Fund...

Marketscreener

OncoZenge AB Stock

Aug. 31 Sichuan Yangtian Bio-Pharmaceutical Fails to Meet Deadline for Fourth Tranche of OncoZenge Investment MT...

Placera.se

OncoZenge - Rights issue funds Phase III execution

OncoZenge - Rights issue funds Phase III execution The issue secures the company’s near-term liquidity, is approximately 80 percent covered, and is backed by guarantees...

Unlock all articles with a

Never miss news about OncoZenge

Track OncoZenge and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.